TL;DR
- Robert Kramer, former CEO of Emergent BioSolutions, allegedly sold Emergent stock while aware of undisclosed contamination problems affecting AstraZeneca COVID-19 vaccine production.
- Kramer set up a Rule 10b5-1 trading plan in October–November 2020, shortly after learning of the contamination issues, and made over $10.1 million from subsequent sales.
- New York Attorney General Letitia James sued Kramer under the state’s Martin Act on January 15, 2026.
- Emergent BioSolutions settled separately, agreeing to pay $900,000 for approving Kramer’s trading plan.
- Kramer has since sought to remove the case to federal court, arguing he acted as an effective federal officer during the pandemic.
In 2020, at the height of Operation Warp Speed, Emergent BioSolutions entered into contracts worth more than $261 million to manufacture AstraZeneca’s COVID-19 vaccine on a large commercial scale at its Baltimore facility. The company was also producing vaccine material for Johnson & Johnson under a separate arrangement. Emergent’s stock nearly doubled in the months following the AstraZeneca announcement, riding a wave of investor enthusiasm for pandemic-response manufacturers.
The October 2020 Warning Signs
According to the New York Attorney General’s complaint, the picture inside Emergent was far less rosy than its stock price suggested. On October 6, 2020, an executive vice president responsible for manufacturing operations gave Kramer a PowerPoint presentation detailing aborted, contaminated vaccine batches. A week later, on October 13, Emergent concluded internally that multiple additional batches were likely to be lost to contamination — information that had not been disclosed to investors.
Setting Up the Trading Plan
The lawsuit alleges that in mid-October 2020, while this contamination information remained confidential, Kramer instructed his investment adviser to set up a Rule 10b5-1 trading plan — a mechanism ordinarily used by executives to pre-schedule stock sales at set dates and prices, in part to avoid the appearance of trading on inside information. Kramer signed the plan in November 2020. He went on to execute a series of trades through January and early February 2021, repeatedly acquiring and then immediately selling Emergent shares under the plan.
The Fallout
Shortly after Kramer’s trading activity, Emergent’s contamination problems became public. The company was later forced to discard roughly 400 million vaccine doses due to contamination at its Baltimore plant, and its stock price fell sharply — a decline the Attorney General’s complaint says the company has not recovered from. Congress held hearings on the manufacturing failures in 2021, with Kramer testifying before a House subcommittee on the coronavirus crisis.
Regulatory and Legal Response
On January 15, 2026, Attorney General James filed suit against Kramer in New York State court, alleging that he violated the Martin Act — New York’s broad securities fraud statute — by trading while in possession of material nonpublic information about the contamination issues. The same day, the Attorney General’s office announced a separate $900,000 settlement with Emergent itself, resolving allegations that the company improperly approved Kramer’s 10b5-1 plan despite internal knowledge of the unresolved manufacturing problems. As part of the settlement, Emergent agreed to strengthen its internal trading-approval policies.
The Attorney General is seeking disgorgement of Kramer’s trading profits, damages, and costs. Kramer, who retired from Emergent in 2023, has pushed back procedurally: in February 2026 he filed a notice to remove the case to federal court, arguing that the claims effectively arise under federal law, that he functioned as a de facto federal officer during the pandemic response, and that diversity jurisdiction applies because the Attorney General is suing on behalf of New York-based investors, including state retirement funds.
Why It Matters
Legal observers have flagged the case as an unusually aggressive use of state securities law to reach a 10b5-1 trading plan — a mechanism the SEC itself has scrutinized in recent years for potential abuse. The action also signals that state attorneys general, not just the SEC, are willing to pursue pharmaceutical and biodefense executives over pandemic-era disclosure failures, and that companies approving executive trading plans can face direct liability of their own when internal red flags exist at the time a plan is adopted.